BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer question
Related Questions
How does Myomo's performance and valuation compare to peers such as SynTouch or Neuronetics?
How does the company's cash burn and liquidity position look for the rest of 2025?
What is the outlook for upcoming FDA approvals or regulatory milestones that could affect the stock?
Will management comment on M&A activity, partnerships, or licensing deals that could affect the company's growth trajectory?
Will Myomo's Q2 2025 revenue and earnings beat market consensus estimates?
Will the earnings call provide any updates on sales channels, reimbursement rates, or insurance coverage that could impact revenue growth?
How did the company's product revenue and margins compare to the same quarter last year?
What are analysts' revised price targets and target price revisions after the earnings release?
What guidance does management give on the pipeline for new wearable robotic devices?
What guidance will management provide for Q3 2025 and full-year 2025 earnings and revenue?